AI and Autonomy Eli Lilly launches AI-powered drug development platform for biotech operators 'TuneLab' allows biotech companies to securely use Eli Lilly's AI models to gain insights about their IP Rowan Dunne2 days ago
Psychedelics Pharma giant AbbVie to spend over US$1B on Gilgamesh’s lead psychedelic One of the biggest deals of all time in the industry Rowan DunneAugust 27, 2025
Medical and Pharmaceutical Y-mAbs stock soars over 100% after acquisition deal with SERB S.A.S. The stock opened at USD$8.54 and traded as high as USD$8.59 before dipping briefly to USD$4.20 before ending the day at USD$8.52 Joseph MortonAugust 5, 2025
Medical and Pharmaceutical Lantern Pharma completes Japanese enrolment for lung cancer drug trial Japan has an extremely high rate of non-smokers getting diagnosed with the disease Rowan DunneAugust 5, 2025
Medical and Pharmaceutical Evoke Pharma skyrockets on patent allowance for diabetes nasal spray drug GIMOTI is used to treat diabetic gastroparesis -- a complication impacting stomach muscles and digestion Rowan DunneJuly 10, 2025
Psychedelics Mindstate Design Labs uses AI to provide customized psychedelic experiences The biotech startup secured FDA approval for Phase I studies on its lead candidate in September Rowan DunneJune 17, 2025
Medical and Pharmaceutical Soleno Therapeutics pulls in FDA nod for treatment for rare genetic disease This approval is a hard-won victory for Soleno after a lengthy clinical trial phase Joseph MortonMarch 27, 2025
Psychedelics Intranasal delivery tech developer ‘Polyrizon’ plans to administer psychedelics The Israeli company has an unnamed new partner involved with unspecified psychedelic drugs Rowan DunneMarch 18, 2025
Psychedelics MindBio Therapeutics uses AI speech analysis to see if you’ve taken its LSD drug The biopharma operator's lead drug candidate, MB22001, was created for microdosing Rowan DunneJanuary 24, 2025
Medical and Pharmaceutical Phio Pharmaceuticals skyrockets on skin cancer drug trial success Shareholders are having a pretty stellar Monday with the immense gains Rowan DunneJanuary 13, 2025